Terms: = Germ cell tumor AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
106 results:
1. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract] [Full Text] [Related]
2. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
[TBL] [Abstract] [Full Text] [Related]
3. Synthesis and Evaluation of Novel
Yao J; Fan M; Peng J; Luo H; Lu J
Mol Pharm; 2024 Feb; 21(2):895-903. PubMed ID: 38170629
[TBL] [Abstract] [Full Text] [Related]
4. Systematic review and cumulative analysis of clinical properties of BRAF V600E mutations in PLNTY histological samples.
Baumgartner ME; Lang SS; Tucker AM; Madsen PJ; Storm PB; Kennedy BC
Childs Nerv Syst; 2024 May; 40(5):1361-1366. PubMed ID: 38150037
[TBL] [Abstract] [Full Text] [Related]
5. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
6. Clinical significance of molecular subgroups of polymorphous low-grade neuroepithelial tumor of the young (PLNTY): A small single institutional case series and integrated analysis.
Vuong HG; Alzayadneh E; Reith TP; Eschbacher KL
Pathol Res Pract; 2023 Dec; 252():154922. PubMed ID: 37984047
[TBL] [Abstract] [Full Text] [Related]
7. Spatial distribution and functional relevance of FGFR1 and fgfr2 expression for glioblastoma tumor invasion.
Alshahrany N; Begum A; Siebzehnrubl D; Jimenez-Pascual A; Siebzehnrubl FA
Cancer Lett; 2023 Sep; 571():216349. PubMed ID: 37579831
[TBL] [Abstract] [Full Text] [Related]
8. Age-related next-generation sequencing mutational analysis in 1196 melanomas.
Santamaria-Barria JA; Matsuba C; Khader A; Scholar AJ; Garland-Kledzik M; Fischer TD; Essner R; Salomon MP; Mammen JMV; Goldfarb M
J Surg Oncol; 2023 Jun; 127(7):1187-1195. PubMed ID: 36938777
[TBL] [Abstract] [Full Text] [Related]
9. Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases.
Demleitner M; Erlenbach-Wünsch K; Coras R; Erber R; Polifka I; Eyüpoğlu I; Fuchs F; Hartmann A; Agaimy A
Ann Diagn Pathol; 2023 Apr; 63():152082. PubMed ID: 36634550
[TBL] [Abstract] [Full Text] [Related]
10. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract] [Full Text] [Related]
11. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract] [Full Text] [Related]
12. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer.
Lazo De La Vega L; Comeau H; Sallan S; Al-Ibraheemi A; Gupta H; Li YY; Tsai HK; Kang W; Ward A; Church AJ; Kim A; Pinto NR; Macy ME; Maese LD; Sabnis AJ; Cherniack AD; Lindeman NI; Anderson ME; Cooney TM; Yeo KK; Reaman GH; DuBois SG; Collins NB; Johnson BE; Janeway KA; Forrest SJ
JCO Precis Oncol; 2022 Nov; 6():e2200390. PubMed ID: 36446043
[TBL] [Abstract] [Full Text] [Related]
13. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung KL; Luebeck J; Dehkordi SR; Colón CI; Li R; Wong IT; Coruh C; Dharanipragada P; Lomeli SH; Weiser NE; Moriceau G; Zhang X; Bailey C; Houlahan KE; Yang W; González RC; Swanton C; Curtis C; Jamal-Hanjani M; Henssen AG; Law JA; Greenleaf WJ; Lo RS; Mischel PS; Bafna V; Chang HY
Nat Genet; 2022 Nov; 54(11):1746-1754. PubMed ID: 36253572
[TBL] [Abstract] [Full Text] [Related]
14. [Clinicopathological features of polymorphous low-grade neuroepithelial tumor of the young].
Zhao S; Wang J; Li MN; Ding Y; Pan MH; Song K
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):640-646. PubMed ID: 35785835
[No Abstract] [Full Text] [Related]
15. Endometrial, Ovarian, and Peritoneal Involvement by Endometrioid Carcinoma, Yolk Sac tumor, and Endometriosis: Molecular Evidence for a Shared Precursor.
Halling GC; Udager AM; Skala SL
Int J Gynecol Pathol; 2023 May; 42(3):247-253. PubMed ID: 35639393
[TBL] [Abstract] [Full Text] [Related]
16. Oncogenic Fusions in Gliomas: An Institutional Experience.
Polivka J; Svajdler M; Priban V; Mracek J; Kasik P; Martinek P; Ptakova N; Sharif Bagheri M; Shetti D; Pesta M; Potuznik P; Topolcan O
Anticancer Res; 2022 Apr; 42(4):1933-1939. PubMed ID: 35347013
[TBL] [Abstract] [Full Text] [Related]
17. Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
Baldini C; Younan N; Castanon Alvarez E; Ammari S; Alentorn A; Dumont S; Frenel JS; Di Stefano AL; Louvel G; Michot JM; Bahleda R; Postel-Vinay S; Varga A; Marabelle A; Hollebecque A; Bielle F; Hoang-Xuan K; Delattre JY; Dhermain F; Sanson M; Soria JC; Idbaih A; Massard C; Touat M
Eur J Cancer; 2022 Mar; 163():98-107. PubMed ID: 35063776
[TBL] [Abstract] [Full Text] [Related]
18. Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature.
Kurokawa M; Kurokawa R; Capizzano AA; Baba A; Ota Y; Pinarbasi E; Johnson T; Srinivasan A; Moritani T
Neuroradiology; 2022 Jun; 64(6):1255-1264. PubMed ID: 35001164
[TBL] [Abstract] [Full Text] [Related]
19. fgfr2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract] [Full Text] [Related]
20. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
Riobello C; Casanueva Muruais R; Suárez-Fernández L; García-Marín R; Cabal VN; Blanco-Lorenzo V; Franchi A; Laco J; López F; Llorente JL; Hermsen MA
Pigment Cell Melanoma Res; 2022 Jan; 35(1):88-96. PubMed ID: 34547192
[TBL] [Abstract] [Full Text] [Related]
[Next]